Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Shares of Immunovant (IMVT) fell about 6% on Wednesday after its lead drug candidate failed to meet the primary goal of a proof-of-concept study in a form of lupus, prompting the company to stop developing the therapy for that indication.If the current levels hold after the opening bell, IMVT share…